New Once-Daily pill could ease Post-Surgery pain
NCT ID NCT06545097
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new drug called cebranopadol for treating moderate to severe pain after a tummy tuck (abdominoplasty). 279 adults took either a low or high dose of the drug or a placebo once daily for two days. Researchers measured pain levels over time and how much extra pain medicine was needed. The goal is to see if this drug offers a safe and effective option for managing acute pain after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cebranopadol (also called TRN-228)
What this could lead to
If successful, this could provide a new once-daily painkiller for people recovering from surgery, reducing the need for rescue medication.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The drug may not prove significantly better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALLEVIATE 1 Site 001106
Little Rock, Arkansas, 72211, United States
-
ALLEVIATE 1 Site 001110
Bellaire, Texas, 77401, United States
-
ALLEVIATE 1 Site 001111
San Antonio, Texas, 78240, United States
-
ALLEVIATE 1 Site 001112
Miami, Florida, 33014, United States